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A key  success  factor  in  the  vaccination  of  dogs  against  leptospirosis  is  long  term  protection
against  establishment  of the  renal  carrier  state,  in order  to protect  other  dogs,  as  well  as
humans,  against  this  re-emerging  zoonotic  disease.  In this  paper,  we  describe  the  ability  of
a new  European  tetravalent  vaccine  containing  antigen  from  Leptospira  interrogans  (sensu
lato) serogroups  Icterohaemorrhagiae,  Canicola,  Grippotyphosa  and  Australis  to  control
infection  and  renal  excretion  in  dogs  at 12 months  after  vaccination.
In  order  to demonstrate  the  efﬁcacy  of all four vaccine  components,  four  separate  chal-
lenge studies  were  performed.  For  each  study  two groups  of  dogs  were  used  (a  group
receiving  the  leptospirosis  vaccine  and  a control  group).  Twelve  months  after  the  second
vaccination  all dogs  in the vaccine  and  control  groups  were  challenged,  both intraperi-
toneally  and conjunctivally,  using  a pathogenic  challenge  strain  from  one  of four  serogroups.
Parameters  recorded  post-challenge  were:  clinical  signs  of  disease,  change  in  body  temper-
ature,  total  leucocyte  count,  thrombocyte  count,  presence  of  challenge  organisms  in  blood,
urine and  kidney  tissue,  and  evidence  of interstitial  nephritis  at necropsy  four weeks  after
challenge.
The vaccine  was  able  to either  prevent  or signiﬁcantly  reduce  infection  following  chal-
lenge with  the  strains  of all  four serogroups.  The  vaccine  was  also  able  to  prevent  or
signiﬁcantly  reduce  renal  infection  following  Canicola  and  Icterohaemorrhagiae  challenge,
and there  was  a trend  of  reduction  of renal  infection  with  Australis  (serovar  Bratislava).  In
the  case  of  the  Grippotyphosa  study,  challenge  led to  no  detectable  renal  infection  in any
dog  of the control  group.
In  conclusion,  in this study  signiﬁcant  protective  immunity  was  achieved  in  dogs  12
months  after a  basic  vaccination  schedule  of two  doses  against  strains  of serogroups  Cani-
cola,  Icterohaemorrhagiae,  Grippotyphosa  and  Australis.©  2013  The  Authors.  Published  by  Elsevier  B.V.  Open access under CC BY license.∗ Corresponding author at: Department of Microbiological R&D, MSD  Animal H
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. Introduction
Although canine Leptospira vaccines are strictly
egarded as ‘non-core’, many dogs are at risk of disease
nd thus vaccination is widespread in many countries. Tra-
itionally, leptospirosis in dogs has been associated with
erovars from serogroups Canicola and Icterohaemorrha-
iae and bivalent vaccines containing strains from these
erogroups have been used for the last 50 years. In recent
ears however there has been an increasing recognition of
isease associated with serovars from other serogroups; in
he USA from serogroups Grippotyphosa and Pomona and
n Europe predominantly from serogroups Grippotyphosa
nd Australis (Ellis, 2010). As a consequence, in the USA,
here are now a number of tetravalent canine leptospirosis
accines available containing, in addition to traditional
cterohaemorrhagiae and Canicola antigens, strains from
erogroups Grippotyphosa and Pomona. In Europe the
accines are still predominantly bivalent, albeit with
ne recently-introduced trivalent product (serogroups
cterohaemorrhagiae–Canicola–Grippotyphosa). Most
f the available vaccines, whether bivalent, trivalent or
etravalent, are regarded as being effective at controlling
linical disease and preventing mortality but only a few
laim to be able to reduce infection or renal excretion
ollowing challenge; an important property in reducing
he spread of this zoonotic disease (Feigin et al., 1973).
dditionally, concerns have been raised about whether
accine immunity persists for a full 12 months or whether
ore frequent re-vaccination is necessary.
A new European tetravalent vaccine containing anti-
en from Leptospira interrogans (sensu lato) serogroups
cterohaemorrhagiae, Canicola, Grippotyphosa and Aus-
ralis has recently been developed (Nobivac® L4 – MSD
nimal Health) which has been shown to reduce infection
nd/or renal excretion following challenge with speciﬁc
erovars of these four serogroups shortly after vaccination
Klaasen et al., 2013). The following studies demonstrate
he ability of this new vaccine to control infection and renal
xcretion in dogs at 12 months after vaccination.
. Materials and methods
.1. Animals
Six-week-old conventional beagle dogs without
etectable agglutinating serum antibodies against
eptospira serogroups Canicola, Icterohaemorrhagiae,
rippotyphosa and Australis were provided by a commer-
ial supplier. In each of the four studies, treatment groups
with nine dogs per group) consisted of pups of both sexes
nd pups derived from different litters in order to prevent
ender and litter effects interfering with treatment effects.
he selected dogs were free of clinical abnormalities or
isease prior to inclusion in these studies. Husbandry
as the same in each study; during the ﬁrst part of the
tudy (pre-challenge, up to 64 weeks of age) the dogs
ere housed in the dog facilities of the supplier; at the
ge of eight weeks the pups were weaned and for the
hallenge phase of the study the dogs were transferred to
he animal facilities of MSD  Animal Health, where, afternd Immunopathology 158 (2014) 26–29 27
being allowed to acclimatise for seven days, they were
challenged at the age of 65 weeks. All housing systems
used in these studies fully complied with the requirements
of the Federation of European Laboratory Animal Science
Associations (FELASA). The animal studies described in this
paper were conducted after prior written approval by the
responsible ethics review committee and thus this work
follows international, national and institutional guidelines
for humane animal treatment and complies with relevant
legislation.
2.2. Study design
In order to demonstrate the efﬁcacy of all four vaccine
components, four separate challenge studies were under-
taken using the same basic protocol. For each study two
groups of dogs were used. One group (vaccine group) was
vaccinated subcutaneously, twice with Nobivac® DHPPi*
reconstituted in Nobivac® L4 at the ages of 6 and 10 weeks,
and once (at the age of 6 weeks) with Nobivac® KC**
intranasally. The second group (control group) was  vacci-
nated twice with Nobivac® DHPPi reconstituted in Nobivac
Solvent subcutaneously at 6 and 10 weeks of age, and once
(at the age of 6 weeks) with Nobivac KC intranasally. Nobi-
vac Solvent does not affect the immune response to the
DHPPi vaccine, because it is a buffered salt solution, and
Nobivac L4 licensing studies (in 2012 approved by the Com-
mittee for Medicinal Products for Veterinary Use of the
European Medicines Agency) demonstrated that there was
no effect of Nobivac DHPPi or Nobivac KC on the immune
response in dogs to Nobivac L4. For the next year the
dogs were housed under strict infection barrier conditions
which prevented the possibility of exposure to ﬁeld infec-
tion. Twelve months after the second vaccination all dogs
in the vaccine and control groups were challenged, both
intraperitoneally and conjunctivally, using a pathogenic
challenge strain from one of four serogroups. Details of the
grouping, vaccination schedules and challenge are shown
in Table 1. For challenge with all four strains the method
described in a recent publication (Klaasen et al., 2013) was
used. However, to reduce the risk of a failing challenge,
for the Bratislava strain two challenges on two consecutive
days were performed.
2.3. Sample collection and parameters
Post-challenge the dogs were monitored for four weeks
for any clinical signs of disease and change in body temper-
ature. Samples of blood, serum and urine were collected
at intervals during the four weeks following challenge
and were evaluated for total leucocyte count, thrombo-
cyte count and for the presence of challenge organisms or
leptospiral DNA by culture and PCR, respectively (Klaasen
et al., 2003; Ahmed et al., 2009). Four weeks after challenge
the dogs were euthanized and a detailed post-mortem
examination was undertaken. In addition a sample of
kidney cortex was taken aseptically for leptospiral cul-
ture. In this study it was crucial to differentiate between
dogs in which direct or indirect evidence was  only found
for leptospiraemia (early phase of the infection) and
dogs in which renal infection (subsequent phase of the
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Table 1
Details of grouping, vaccination and challenge.
Study Group No. of dogs 1st vaccination 2nd vaccination Leptospira challenge
Age (weeks) Vaccines Age (weeks) Vaccines Age (weeks) Serogroup Serovar
1 Vaccine 9 6 L4, DHPPia, KCb 10 L4, DHPPi 65 Canicola Canicola
Control 9 6 DHPPi, KC 10 DHPPi 65 Canicola Canicola
2  Vaccine 9 6 L4, DHPPi, KC 10 L4, DHPPi 65 Icteroh. Copenhageni
Control 9 6 DHPPi, KC 10 DHPPi 65 Icteroh. Copenhageni
3  Vaccine 9 6 L4, DHPPi, KC 10 L4 + DHPPi 65 Gripp. Bananal/Liangguang
Control 9 6 DHPPi, KC 10 DHPPi 65 Gripp. Bananal/Liangguang
4  Vaccine 9 6 L4, DHPPi, KC 10 L4, DHPPi 65 Australis Bratislava
Control 9 6 DHPPi, KC 10 DHPPi 65 Australis Bratislava
a Nobivac DHPPi – live, freeze-dried vaccine containing canine distemper virus, canine adenovirus type 2, canine parvovirus and canine parainﬂuenza
eptica a
virus for subcutaneous inoculation following reconstitution.
b Nobivac KC – live, freeze-dried vaccine containing Bordetella bronchis
stitution.
infection) was demonstrated. In accordance with the Euro-
pean Pharmacopoeia Monograph 0447 [“Canine Leptospi-
rosis vaccine (Inactivated)”] the somewhat arbitrary term
infection (referring to the bacteraemic phase of the infec-
tion) and the term renal infection (referring to urinary tract
infection and excretion) are used here to assess per chal-
lenge strain the numbers of dogs with infection and renal
infection in vaccinated groups versus control groups. The
following criteria were used to deﬁne a dog positive for
infection and renal infection:
• A dog positive for infection (early stage of leptospirosis
in which leptospiraemia plays a central role) is a dog
with at least two positive samples of blood or serum or
urine/kidney on different days or a dog with challenge-
induced nephritis or clinical or haematological evidence
for leptospirosis.In general, an initial phase of bacter-
aemia (i.e., leptospiraemia) has occurred in each dog in
which infection, even in the absence of positive blood
samples, or renal infection has been demonstrated, since:
(i) challenge-induced clinical signs or haematological
changes in the ﬁrst two weeks are associated with bac-
teraemia, because these are effects of leptospires in the
bloodstream (Faine, 1994a); (ii) in any dog in which chal-
lenge organisms are isolated from urine or kidney and
in any dog with challenge-induced nephritis a preced-
ing phase of bacteraemia has occurred: the bacteria are
disseminated from the bloodstream, and not via another
route, to the kidneys (Faine, 1994a, 1998).
• A dog positive for renal infection is a dog with at
least one positive sample of urine/kidney from day 14
post-challenge onwards or challenge-induced nephritis
(demonstrated by histopathological examination).This
deﬁnition is considered valid, since: (i) the presence
of leptospires in urine or kidney tissue from day 14
post-challenge onwards is considered as evidence for an
active renal infection based on generally known scientiﬁc
data on renal disease and patterns of urinary excretion
in canine leptospirosis (Faine, 1998; Levett, 2001); (ii)
challenge-induced nephritis is a result of ischaemia and
inﬂammation caused by the prolonged presence of lep-
tospires in the blood vessels of the kidney (Faine, 1994a;
Levett, 2001).The numbers of dogs which were scored
as positive for infection and renal infection in each ofnd canine parainﬂuenza virus for intranasal inoculation following recon-
the four challenge studies were recorded and then com-
pared to identify signiﬁcant differences using a two-sided
Fisher’s Exact test.
3. Results and discussion
Although in the USA serovar Bratislava has been
reported as a pathogen in dogs (Adin and Cowgill, 2000),
it is mainly in Europe where this serovar has been recog-
nised as a dog pathogen (Ellis, 2010). In the present study
the Bratislava strain was  able to persist in the bloodstream
of non-vaccinated control dogs for up to four days and to
appear in the urine on days 3, 16 and 22 post-challenge,
and caused interstitial nephritis in two control dogs (results
not shown). These results clearly demonstrate the dog-
pathogenicity of Bratislava.
The results are summarised in Table 2. As can be seen the
vaccine was able to either prevent or signiﬁcantly reduce
infection following challenge one year after vaccination in
all four studies. The vaccine was also able to prevent or
signiﬁcantly reduce renal infection following Canicola and
Icterohaemorrhagiae challenge one year after vaccination.
In the Canicola challenge study one out of nine vaccinated
dogs had a positive urine culture on three out of ﬁve post-
challenge sampling points, but without any evidence of
leptospiral infection in the kidney (negative on renal cul-
ture and no signs of interstitial nephritis) at the end of the
study. Nonetheless this dog was classiﬁed as “positive for
infection” and “positive for renal infection” according to
the criteria described. None of the other vaccinated dogs
had any positive urine, whereas in all control dogs con-
vincing evidence of renal infection was  found (multiple
positive urine cultures, interstitial nephritis). In the case of
Australis challenge the difference between vaccinated and
control dogs with renal infection was  too small to reach
statistical signiﬁcance (P = 0.0824), due to a low number of
positive control dogs (four out of nine control dogs). How-
ever, there was  a clear tendency of reduction of urinary
shedding by vaccination. With one additional control dog
being positive the difference would have been statistically
signiﬁcant (P = 0.0294). Apart from the four positive control
dogs, a ﬁfth control dog had a positive urine sample on day
3 post-challenge but the other urine samples were nega-
tive, so that this dog was classiﬁed as negative for renal
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Table  2
Numbers of dogs positive for infection or renal infection post-challenge.
Study (challenge) Group No. of dogs/group positive for:
Infection Renal infection
No. of dogs Signiﬁcant? No. of dogs Signiﬁcant?
1 (Canicola) Vaccine 1/9 S (P = 0.0004) 1/9a S (P = 0.0004)
Control 9/9 9/9
2  (Icteroh.) Vaccine 0/9 S (P = 0.0091) 0/9 S (P = 0.0091)
Control 6/9 6/9
3  (Gripp.) Vaccine 1/8b S (P = 0.0152) 1/8b NS (P = 0.4706)
Control 7/9 0/9
4  (Australis) Vaccine 2/8 S (P = 0.0152) 0/8 NS (P = 0.0824)
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a Dog had three positive urine samples; no clinical signs, no thrombocy
b Dog had interstitial nephritis; no positive culture/PCR results, no clin
nfection (results not shown). In the case of the Grippo-
yphosa study, challenge did not lead to detectable renal
nfection in any of the control group. In contrast, a similar
hallenge study in our laboratory using the same chal-
enge (strain, method and dose) carried out in puppies at 13
eeks of age induced signs of renal infection in seven out
f eight control dogs (Klaasen et al., 2013). Apart from the
ratislava study where a repeated challenge on two  con-
ecutive days was performed, it was observed that fewer
ontrol dogs had positive blood and or urine cultures in
he present studies involving challenge in adult dogs than
n the previously published studies with challenge in pups.
his discrepancy can be explained by the fact that adult
nimals are known to have a higher resistance to infection
ith pathogenic Leptospira bacteria compared to young
nimals (Faine, 1994b). In the present Grippotyphosa chal-
enge study there was also one vaccinated dog with signs of
nterstitial nephritis at post-mortem but with no evidence
f the presence of leptospires (by either culture or PCR) and
o clinical signs or evidence of thrombocytopaenia (results
ot shown). Although this case, according to the deﬁnition
f a dog positive for renal infection, has been scored as a
ositive case it is likely that the interstitial nephritis could
ave resulted from some other cause.
In these studies we were able to reproduce transient
eptospiraemia and urinary shedding of the challenge
rganisms in non-vaccinated control dogs following chal-
enge with pathogenic strains from serogroups Canicola,
cterohaemorrhagiae and Bratislava, and transient lep-
ospiraemia for Grippo typhosa. With this vaccine urinary
hedding of leptospires is reduced, which implies that the
accine helps prevent transmission of the infection to other
nimals and to humans and, therefore, is an aid in preven-
ing these zoonotic infections (Feigin et al., 1973).
. ConclusionIn this study signiﬁcant protective immunity was
chieved in dogs 12 months after a basic vaccination
chedule of two doses against strains of serogroups4/9
, no positive kidney, no interstitial nephritis.
s, no thrombocytopenia.
Canicola, Icterohaemorrhagiae, Grippotyphosa and Aus-
tralis. Reduction of infection (leptospiraemia) was  demon-
strated against a Grippotyphosa strain, and reduction
of infection, renal infection and urinary shedding was
demonstrated against strains of serogroups Canicola,
Icterohaemorrhagiae and Australis.
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